Raphael Pharmaceutical (RAPH) Net Income towards Common Stockholders (QoQ) (2021 - 2024)
Raphael Pharmaceutical (RAPH) Net Income towards Common Stockholders (QoQ) (2021 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -505.64% |
| Sep 30, 2024 | -28.11% |
| Jun 30, 2024 | 54.48% |
| Mar 31, 2024 | 51.85% |
| Dec 31, 2023 | -55.83% |
| Sep 30, 2023 | -73.99% |
| Jun 30, 2023 | -62.40% |
| Mar 31, 2023 | 85.91% |
| Dec 31, 2022 | -28.40% |
| Sep 30, 2022 | -133.01% |
| Jun 30, 2022 | -249.71% |
| Mar 31, 2022 | 90.37% |
| Dec 31, 2021 | -334.69% |
| Sep 30, 2021 | -8.57% |
| Jun 30, 2021 | -52.78% |
| Mar 31, 2021 | 34.55% |